Article Text

Download PDFPDF
Systematic review
Prognostic value of CRP in stable coronary artery disease unclear due to a variety of biases in existing studies, therefore no clinical practice recommendations can be made
  1. Vlado Perkovic1,
  2. Rachel Huxley1
  1. 1George Institute for Global Health, Camperdown, New South Wales, Australia
  1. Correspondence to Vlado Perkovic
    PO Box M201, Missenden Road, Camperdown NSW 2070, Australia; vperkovic{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Individuals with cardiovascular disease (CVD) are at high risk for further cardiovascular events. Further risk stratification in these individuals could allow more precise targeting of invasive tests (eg, cardiac stress tests, angiograms) as well as interventions (blood pressure or lipid lowering, antithrombotics, revascularisation, etc) aiming to reduce subsequent risk but which also confer risk, inconvenience and costs to the individual and/or the healthcare system. Better methods of risk stratification are therefore of great interest.

C reactive protein (CRP) is an inflammatory marker associated with risk in people without CVD.1 The review by Hemingway and colleagues aimed to consolidate the available evidence assessing CRP as a risk marker in people with coronary artery disease and to assess whether there was evidence of bias affecting …

View Full Text


  • Competing interests None.